Continued CD4 cell count increases in HIV-infected adults experiencing 4 years of viral suppression on antiretroviral therapy

AIDS

Volumn 17, Issue 13, 2003, Pages 1907-1915

  Hunt, Peter W ^a,b   Deeks, Steven G ^a   Rodriguez, Benigno ^c   Valdez, Hernan ^c   Shade, Starley B ^a,d   Abrams, Donald I ^a,d   Kitahata, Mari M ^e   Krone, Melissa ^f   Neilands, Torsten B ^f   Brand, Richard J ^a,f   Lederman, Michael M ^c   Martin, Jeffrey N ^a,f,g  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b SAN FRANCISCO VETERANS AFFAIRS MEDICAL CENTER   (United States)

^c CASE WESTERN RESERVE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d Community Consortium ^*  (United States)

^e UNIVERSITY OF WASHINGTON   (United States)

^f UNIVERSITY OF CALIFORNIA   (United States)

^g UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Antiretroviral therapy; CD4 cell count; Drug effects; HAART; HIV 1

Indexed keywords

ABACAVIR; ANTIRETROVIRUS AGENT; CD4 ANTIGEN; PROTEINASE INHIBITOR; RITONAVIR; RNA DIRECTED DNA POLYMERASE INHIBITOR;

ADULT; ARTICLE; COHORT ANALYSIS; CORRELATION ANALYSIS; DRUG EFFECT; EVALUATION; FEMALE; FOLLOW UP; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNE SYSTEM; LYMPHOCYTE COUNT; MAJOR CLINICAL STUDY; MALE; NONHUMAN; PRIORITY JOURNAL; T LYMPHOCYTE SUBPOPULATION; TIME SERIES ANALYSIS; VIREMIA; VIRUS LOAD;

ADULT; ANTI-HIV AGENTS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; CD4 LYMPHOCYTE COUNT; COHORT STUDIES; FEMALE; FOLLOW-UP STUDIES; HIV INFECTIONS; HIV-1; HUMANS; MALE; MIDDLE AGED; RNA, VIRAL; VIRAL LOAD;

EID: 0041326880     PISSN: 02699370     EISSN: None     Source Type: Journal    
DOI: 10.1097/00002030-200309050-00009     Document Type: Article

References (40)

1. DHHS and Kaiser Family Foundation Guidelines for the use of antiretroviral agents in HIV-infected adults and adolescents. 2002.
2. Notermans DW, Pakker NG, Hamann D, Foudraine NA, Kauffmann RH, Meenhorst PL, et al. Immune reconstitution after 2 years of successful potent antiretroviral therapy in previously untreated human immunodeficiency virus type 1-infected adults. J Infect Dis 1999, 180:1050-1056.
3. Gulick RM, Mellors JW, Havlir D, Eron JJ, Meibohm A, Condra JH, et al. 3-year suppression of HIV viremia with indinavir, zidovudine, and lamivudine. Ann Intern Med 2000, 133:35-39.
4. Tarwater PM, Margolick JB, Jin J, Phair JP, Detels R, Rinaldo C, et al. Increase and plateau of CD4 T-cell counts in the 3 1/2 years after initiation of potent antiretroviral therapy. J Acquir Immune Defic Syndr 2001, 27:168-175.
5. Staszewski S, Miller V, Sabin C, Schlecht C, Gute P, Stamm S, et al. Determinants of sustainable CD4 lymphocyte count increases in response to antiretroviral therapy. AIDS 1999, 13:951-956.
6. Wood E, Yip B, Hogg RS, Sherlock CH, Jahnke N, Harrigan RP, et al. Full suppression of viral load is needed to achieve an optimal CD4 cell count response among patients on triple drug antiretroviral therapy. AIDS 2000, 14:1955-1960.
7. Le Moing V, Thiebaut R, Chene G, Leport C, Cailleton V, Michelet C, et al. Predictors of long-term increase in CD4(+) cell counts in human immunodeficiency virus-infected patients receiving a protease inhibitor- containing antiretroviral regimen. J Infect Dis 2002, 185:471-480.
8. Deeks SG, Barbour JD, Grant RM, Martin JN. Duration and predictors of CD4 T-cell gains in patients who continue combination therapy despite detectable plasma viremia. AIDS 2002, 16:201-207.
9. Kaufmann GR, Bloch M, Finlayson R, Zaunders J, Smith D, Cooper DA. The extent of HIV-1-related immunodeficiency and age predict the long- term CD4 T lymphocyte response to potent antiretroviral therapy. AIDS 2002, 16:359-367.
10. Valdez H, Connick E, Smith KY, Lederman MM, Bosch RJ, Kim RS, et al. Limited immune restoration after 3 years' suppression of HIV-1 replication in patients with moderately advanced disease. AIDS 2002, 16:1859-1866.
11. Deeks SG, Hecht FM, Swanson M, Elbeik T, Loftus R, Cohen PT, et al. HIV RNA and CD4 cell count response to protease inhibitor therapy in an urban AIDS clinic: response to both initial and salvage therapy. AIDS 1999,13:F35-F43.
12. Valdez H, Chowdhry TK, Asaad R, Woolley IJ, Davis T, Davidson R, et al. Changing spectrum of mortality due to human immunodeficiency virus: analysis of 260 deaths during 1995-1999. Clin Infect Dis 2001, 32:1487-1493.
13. Deeks SG, Barbour JD, Martin JN, Swanson MS, Grant RM. Sustained CD4+ T-cell response after virologic failure of protease inhibitor-based regimens in patients with human immunodeficiency virus infection. J Infect Dis 2000, 181:946-953.
14. Anastassopoulou CG, Touloumi G, Katsoulidou A, Hałzitheadoru H, Pappa M, Paraskevis D, et al. Comparative evaluation of the QUANTIPLEX HIV-1 RNA 2.0 and 3.0 (bDNA) assays and the AMPLICOR HIV-1 MONITOR v1.5 test for the quantitation of human immunodeficiency virus type 1 RNA in plasma. J Virol Methods 2001, 91:67-74.
15. Burnham KP, Anderson DR. Model Selection and Inference: A Practical Information-Theoretic Approach. New York: Springer-Verlag, Inc.; 1988.
16. Jennrich RI, Schluchter MD. Unbalanced repeated-measures models with structured covariance matrices. Biometrics 1986, 42:805-820.
17. Laird NM. Missing data in longitudinal studies. Stats Med 1988, 7:305-315.
18. Duan N. Smearing estimation: a non parametric retransformation method. J Am Stat Assoc 1983, 78:605-610.
19. Pakker NG, Notermans DW, de Boer RJ, Roos MT, de Wolf F, Hill A, et al. Biphasic kinetics of peripheral blood T-cells after triple combination therapy in HIV-1 infection: a composite of redistribution and proliferation. Nature Med 1998, 4:208-214.
20. Sousa AE, Chaves AF, Doroana M, Antunes F, Victorino RM. Kinetics of the changes of lymphocyte subsets defined by cytokine production at single cell level during highly active antiretroviral therapy for HIV-1 infection. J Immunol 1999, 162:3718-3726.
21. Bucy RP, Hockett RD, Derdeyn CA, Saag MS, Squires KE, Sillers M, et al. Initial increase in blood CD4(+) lymphocytes after HIV antiretroviral therapy reflects redistribution from lymphoid tissues. J Clin Invest 1999, 103:1391-1398.
22. Smith KY, Valdez H, Landay A, Spritzler J, Kessler HA, Connick E, et al. Thymic size and lymphocyte restoration in patients with human immunodeficiency virus infection after 48 weeks of zidovudine, lamivudine, and ritonavir therapy. J Infect Dis 2000, 181:141-147.
23. Teixeira L, Valdez H, McCune JM, Koup RA, Badley AD, Hellerstein MK, et al. Poor CD4 T-cell restoration after suppression of HIV-1 replication may reflect lower thymic function. AIDS 2001, 15:1749-1756.
24. Douek DC, McFarland RD, Keiser PH, Gage EA, Massey JM, Haynes BF, et al. Changes in thymic function with age and during the treatment of HIV infection. Nature 1998, 396: 690-695.
25. Hakim FT, Cepeda R, Kaimei S, Mackall CL, McAtee N. Constraints on CD4 recovery postchemotherapy in adults: thymic insufficiency and apoptotic decline of expanded peripheral CD4 cells. Blood 1997, 90:3789-3798.
26. Anthony K, Sereti I, Orenstein J, Der Simonian R, Herpin B, Metcalf JA, et al. T-cell turnover does not normalize after 24 weeks of HAART and remains elevated in patients with failure of CD4 recovery despite effective viral suppression. XIV International Conference on AIDS. Barcelona, July 2002 [abstract WePeA5734].
27. + T cell gains in HIV-infected patients with sustained viral suppression during antiretroviral therapy. J Infect Dis 2003, 187:1534-1543.
28. Giorgi JV, Hultin LE, McKeating JA, Johnson TD, Owens B, Jacobson LP, et al. Shorter survival in advanced human immunodeficiency virus type 1 infection is more closely associated with T lymphocyte activation than with plasma virus burden or virus chemokine coreceptor usage. J Infect Dis 1999, 179:859-870.
29. Lederman MM, McKinnis R, Kelleher D, Cutrell A, Mellors J, Neisler M, et al. Cellular restoration in HIV infected persons treated with abacavir and a protease inhibitor: age inversely predicts naive CD4 cell count increase. AIDS 2000, 14:2635-2642.
30. Viard JP, Mocroft A, Chiesi A, Kirk O, Roge B, Panos G, et al. Influence of age on CD4 cell recovery in human immunodeficiency virus-infected patients receiving highly active antiretroviral therapy: evidence from the EuroSIDA study. J Infect Dis 2001, 183:1290-1294.
31. Giordano TP, Visnegarwala F, Wright JA, Adu-Oppong A, Graviss EA. Gender but not ethnicity predicts CD4 cell increase in response to sustained virologic suppression (SVS) from highly active antiretroviral therapy (HAART). XIV International Conference on AIDS. Barcelona, July 2002 [abstract WePeB5965].
32. Keiser P, Nassar NN, Koen G, Moreno S. Comparison of virologic response in a cohort of women and men treated with nelfinavir containing HAART regimens. XIV International Conference on AIDS. Barcelona, July 2002 [abstract WePeB5962].
33. Palella FJ, Jr., Gathe J, Brutus A, Sension M, Allen B, Morrow P. Gender comparisons in long term responses among patients receiving nelfinavir and dual nucleoside reverse transcriptase inhibitors as first ever highly active antiretroviral therapy. XIV International Conference on AIDS. Barcelona, July 2002 [abstract WePeB5967].
34. Sklar PA, Ward DJ, Baker RK, Wood KC, Gafoor Z, Alzola CF, ^S et al. Prevalence and clinical correlates of HIV viremia ('blips') in patients with previous suppression below the limits of quantification. AIDS 2002, 16:2035-2041.
35. Hogg RS, Yip B, Chan KJ, Wood E, Craib KJP, O'Shaughnessy MV, et al. Rates of disease progression by baseline CD4 cell count and viral load after initiating triple-drug therapy. JAMA 2001, 286:2568-2577.
36. Sterling TR, Chaisson RE, Moore RD. HIV-1 RNA, CD4 T-lymphocytes, and clinical response to highly active antiretroviral therapy. AIDS 2001, 15:2251-2257.
37. Egger M, May M, Chene G, Phillips AN, Ledergerber B, Dabis F, et al. Prognosis of HIV-1-infected patients starting highly active antiretroviral therapy: a collaborative analysis of prospective studies. Lancet 2002, 360:119-129.
38. Lange C, Valdez H, Medvik K, Asaad R, Wild M, Kalayiian R, et al. Earlier initiation of HAART better preserves functional immune competence even in persons who achieve 'normal' CD4+ T-cell counts. XIV International Conference on AIDS. Barcelona, July 2002 [abstract Lb0r09].
39. Lucas GM, Chaisson RE, Moore RD. Highly active antiretroviral therapy in a large urban clinic: risk factors for virologic failure and adverse drug reactions. Ann Intern Med 1999, 131:81-87.
40. Valdez H, Lederman MM, Woolley I, Walker CJ, Vernon LT, Hise A, et al. Human immunodeficiency virus 1 protease inhibitors in clinical practice: predictors of virological outcome. Arch Intern Med 1999, 159:1771-1776.